Regulatory Insights

  1. Fear Isn't A Strategy: Rethinking AI In Clinical Trials 3/16/2026

    As AI restrictions rise, needed oversight is slowing trials. This piece explores how delays hurt patients and how sites and sponsors can modernize without sacrificing regulatory trust.

  2. European Clinical Supply Planning – Balancing Cost, Flexibility, And Time 3/13/2026

    By evaluating the key parameters of a study, sponsors can identify the most effective location for packaging and distributing clinical trial supplies.

  3. Optimizing Clinical Trials In China With Strategic Solutions For Supply Chain 3/12/2026

    Plan proactively for clinical trials in China by aligning with National Medical Products Administration requirements and leveraging Free Trade Zones to streamline regulatory approvals and clinical supply importation.

  4. The Bioanalysis CRO Selection Checklist Every Sponsor Should Use Before Signing An MSA 3/9/2026

    Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

  5. GLP Compliance In A Modern Lab: What Compliant Actually Requires In 2025 3/9/2026

    GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

  6. Why ddPCR Is Becoming The Standard For Gene Therapy Biodistribution 3/9/2026

    ddPCR is becoming essential for biodistribution because it delivers precise, low‑copy quantification qPCR can’t reliably match. Sponsors need partners with true ddPCR depth to ensure consistent, defensible data across tissues and studies.

  7. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  8. Why CGT Programs Need A Different CRO Mindset 3/9/2026

    Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

  9. The Bioanalysis Report You Actually Get Back Fast 3/9/2026

    Manual bioanalysis variability creates data noise. Automation replaces inconsistencies with repeatable processes that boost precision, support compliance, and deliver more reliable results.

  10. ICH E6(R3) Is Here: What Your Centralized Monitoring Strategy Needs 3/9/2026

    ICH E6(R3) turns best practices into regulatory mandates. Learn how to maintain sponsor accountability and implement proportionate centralized monitoring through a unified, auditable data layer.